On April 25, 2023 Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") reported its financial results for the first quarter of fiscal year 2023, which include the consolidated financial results for GRAIL (Press release, Illumina, APR 25, 2023, View Source [SID1234630470]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The year is off to a solid start, led by NovaSeq X outperforming expectations in both customer demand and manufacturing supply," said Francis deSouza, Chief Executive Officer. "We shipped 67 NovaSeq X instruments in the first quarter, exceeding our plan. Demand remains strong, with our quarter-end NovaSeq X order book standing at over 200 instruments. We continue to work closely with our customers and partners to help them manage the challenging macroeconomic environment and to deliver on our 2023 goals. Our commitment to higher margins will set Illumina on the best path to deliver long-term sustainable success for our shareholders."

First quarter consolidated results
GAAP Non-GAAP (a)
Dollars in millions, except per share amounts Q1 2023 Q1 2022 Q1 2023 Q1 2022
Revenue $ 1,087 $ 1,223 $ 1,087 $ 1,223
Gross margin 60.3 % 66.6 % 64.7 % 69.9 %
Research and development ("R&D") expense $ 341 $ 323 $ 339 $ 323
Selling, general and administrative ("SG&A") expense $ 378 $ 308 $ 343 $ 320
Operating (loss) profit $ (64) $ 184 $ 21 $ 212
Operating margin (5.7) % 15.0 % 1.9 % 17.3 %
Tax rate 103.9 % 38.3 % 27.3 % 17.8 %
Net income $ 3 $ 86 $ 13 $ 169
Diluted earnings per share $ 0.02 $ 0.55 $ 0.08 $ 1.07

(a) See the tables included in the "Results of Operations – Non-GAAP" section below for reconciliations of these GAAP and non-GAAP financial measures.

__________________________________
1 The company only provides non-GAAP measures for operating margin targets because of the difficulty of projecting with reasonable certainty the financial impact of specific GAAP operating adjustments. Please see Illumina’s "Statement regarding use of non-GAAP financial measures" for more information.

Capital expenditures for free cash flow purposes were $52 million for Q1 2023. Cash flow provided by operations was $10 million, compared to $172 million in the prior year period. Free cash flow (cash flow provided by operations less capital expenditures) was $(42) million for the quarter, compared to $111 million in the prior year period. Depreciation and amortization expenses were $107 million for Q1 2023. At the close of the quarter, the company held $1,518 million in cash, cash equivalents and short-term investments, compared to $2,037 million as of January 1, 2023. During the first quarter, the company used $500 million to repay the outstanding principal of our 2023 term notes that matured in March.

First quarter segment results
Illumina has two reportable segments, Core Illumina and GRAIL.

Core Illumina
GAAP Non-GAAP (a)
Dollars in millions Q1 2023 Q1 2022 Q1 2023 Q1 2022
Revenue (b)
$ 1,076 $ 1,221 $ 1,076 $ 1,221
Gross margin (c)
63.8 % 69.7 % 65.2 % 70.2 %
R&D expense $ 259 $ 238 $ 257 $ 238
SG&A expense $ 286 $ 251 $ 257 $ 267
Operating profit $ 142 $ 362 $ 187 $ 352
Operating margin 13.2 % 29.6 % 17.4 % 28.8 %

(a) See Table 3 included in the "Results of Operations – Non-GAAP" section below for reconciliations of these GAAP and non-GAAP financial measures.
(b) Core Illumina revenue for Q1 2023 was down 12% from Q1 2022, and down 10% on a constant currency basis. Amounts for Q1 2023 and Q1 2022 included intercompany revenue of $9 million and $8 million, respectively, which is eliminated in consolidation.
(c) The year-over-year decrease in gross margin was primarily driven by less fixed cost leverage on lower manufacturing volumes and lower instrument margins due to the NovaSeq X launch, which is typical for a new platform introduction.

GRAIL
GAAP Non-GAAP (a)
In millions Q1 2023 Q1 2022 Q1 2023 Q1 2022
Revenue $ 20 $ 10 $ 20 $ 10
Gross (loss) profit $ (25) $ (29) $ 9 $ 5
R&D expense $ 86 $ 85 $ 86 $ 85
SG&A expense $ 93 $ 58 $ 87 $ 54
Operating loss $ (204) $ (172) $ (164) $ (134)

(a) See Table 3 included in the "Results of Operations – Non-GAAP" section below for reconciliations of these GAAP and non-GAAP financial measures.

Key announcements by Illumina since Illumina’s last earnings release
•Launched Illumina Complete Long Read Prep, Human, which enables access to both long- and short-read data on the same instrument for the first time
•Partnered with Henry Ford Health, a not-for-profit health care organization in the Detroit metro area, to assess the impact of comprehensive genomic testing in cardiovascular disease
•Launched Illumina Connected Insights, a new cloud-based software enabling tertiary analysis for clinical next-generation sequencing (NGS) data, with applications for oncology and soon rare diseases
•Celebrated the company’s 25th anniversary, a quarter-century after its founding in San Diego in April 1998

•Expanded strategic partnership with Myriad Genetics to broaden access and availability of oncology homologous recombination deficiency (HRD) testing in the United States; under the agreement, Illumina TruSight Oncology 500 HRD (TSO 500 HRD), a research-use-only test, is now available in the US
•Received the international privacy certification (ISO/IEC 27701) of six of Illumina’s cloud-based informatics programs, recognizing that the company implements, and complies with, robust, international data privacy requirements
•Exceeded more than 200 orders for the revolutionary NovaSeq X, representing a diverse customer base spanning research and clinical customer segments in nearly 30 countries
•Was granted expedited appellate review of the FTC order to divest GRAIL

A full list of recent Illumina announcements can be found in the company’s News Center.

Key announcements by GRAIL since Illumina’s last earnings release
•Announced that the 140,000 participant NHS trial has successfully reached its halfway point, with over half of the study participants having returned for their second annual blood draw, and is currently progressing as planned to achieve its targeted retention rates
•Announced that FirstHealth of the Carolinas, Inc., a health system serving patients in 15 counties in the mid-Carolinas, will offer Galleri to eligible patients in North Carolina
•Expanded existing partnership with Providence Health System, one of the largest health systems in the western US, to offer multi-cancer early detection screening as part of clinical care to eligible individuals across the entire Providence health system, consisting of 53 hospitals and 900 clinics across seven states
•Announced that John Hancock, one of the largest life insurers in the US, expanded access to Galleri to eligible life insurance customers participating in the John Hancock Vitality PLUS program following a successful pilot program
•Presented new data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 showcasing the performance of its methylation technology, which had a cancer detection rate of 92% in patients with relapsed or refractory disease across six hematological malignancies

A full list of recent GRAIL announcements can be found in GRAIL’s Newsroom.

Financial outlook and guidance
The non-GAAP financial guidance discussed below reflects certain pro forma adjustments to assist in analyzing and assessing our core operational performance, including the company’s Core Illumina and GRAIL segments. Please see our Reconciliation of Consolidated Non-GAAP Financial Guidance included in this release for a reconciliation of these GAAP and non-GAAP financial measures.

For fiscal year 2023, the company continues to expect consolidated revenue growth of 7% to 10% compared to fiscal year 2022. The company continues to expect Core Illumina revenue growth of 6% to 9% compared to fiscal year 2022. GRAIL revenue is still expected to be in the range of $90 million to $110 million.

The company now expects GAAP diluted loss per share of $(0.28) to $(0.03) and still expects non-GAAP diluted earnings per share of $1.25 to $1.50. The GAAP and non-GAAP diluted (loss) earnings per share guidance ranges continue to assume that the existing R&D capitalization requirements are not repealed in fiscal year 2023 and, as a result, reflect a tax expense impact of approximately $75 million.

Commitment to higher margins; announcing $100 million in run rate cost savings
The company commits to achieving Core Illumina non-GAAP operating margins of 25% in 2024 and 27% in 2025.

Building on the cost reduction steps announced in November 2022, Illumina will further reduce its annualized run rate expenses by more than $100 million beginning later in 2023. These cost savings will accelerate progress toward higher margins as well as free up capital to increase investment in high-growth areas. The company will continue to prioritize and invest in initiatives that generate highly differentiated products that are valued by Illumina’s customers.

Illumina will achieve these savings through a combination of several actions. We will leverage the recent modularization of R&D innovation created as part of the NovaSeq X development, including XLEAP-SBS and new flow cell technology, to lower the cost and accelerate time to market for future platforms. The company will achieve additional savings through leveraging its global footprint, enabling activities at more cost-effective hubs. The company is also streamlining its organization and processes, including rationalizing its global real estate portfolio and third-party vendor spend, as well as accelerating IT optimization efforts.

The company only provides non-GAAP measures for operating margin targets because of the difficulty of projecting with reasonable certainty the financial impact of specific GAAP operating adjustments. Please see Illumina’s "Statement regarding use of non-GAAP financial measures" for more information.

Conference call information
The conference call will begin at 2 p.m. Pacific Time (5 p.m. Eastern Time) on Tuesday, April 25, 2023. Interested parties may access the live teleconference through the Investor Info section of Illumina’s website under the "Company" tab at www.illumina.com. Alternatively, individuals can access the call by dialing 877.502.9276 or +1.313.209.4906 outside North America, both using conference ID 1539055. To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.

A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following.

On April 25, 2023 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, reported a research collaboration agreement to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across more than 14 different types of cancer (Press release, Guardant Health, APR 25, 2023, View Source [SID1234630471]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Guardant Health will analyze patient blood samples from PICI’s RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) prospective study of 1,200 individuals on standard-of-care immune checkpoint inhibitor (ICI) treatment regimens in community hospitals. The testing, which will be conducted with GuardantINFINITY, will provide a multi-dimensional analysis of each patient’s tumor response based on both genomic and epigenomic profiling. The study will use blood samples drawn at multiple points during the treatment regimen and will assess the connection between the presence of specific cancer biomarkers and real-world clinical outcomes, including survival and immune-related adverse events.

"By breaking down barriers and forging deep collaboration, PICI can accelerate the development of breakthrough immune therapies and turn all cancers into curable diseases," said Tarak Mody, PhD, chief business officer at PICI. "This mission-focused collaboration with Guardant Health aims to identify the molecular drivers of treatment response in clinical practice, provide significant learnings in PD1 resistance mechanisms, and serve as a valuable resource to the PICI research network for biomarker discovery, target validation, and clinical trial design."

The project marks the first real-world immuno-oncology study collaboration for Guardant Health and will enable the company to significantly expand its access to real-world outcomes data for immunotherapies correlated to specific biomarkers, cancer type and stage.

"The collaborative study with PICI is an excellent opportunity for us to explore the value of genomic and epigenomic tumor profiling in real-world immuno-oncology therapy settings," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "The study will generate deeper insights about the tumor microenvironment and its response to therapy, which will enable us to respond to cancer evolution faster and, eventually, modify immunotherapy treatment paradigms for better patient outcomes."

Guardant Health and PICI intend to begin publishing data generated by the study later in 2023.

On April 25, 2023 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, reported that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ on Tuesday, May 2, 2023 at 11:00 a.m. ET (Press release, CytomX Therapeutics, APR 25, 2023, View Source [SID1234630473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

On April 25, 2023 CureVac N.V. (Nasdaq: CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), reported financial results for the fourth quarter and full-year 2022 and provided a business update (Press release, CureVac, APR 25, 2023, View Source [SID1234630474]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Last year was transformative for CureVac, as we have made significant strides in advancing our unique end-to-end mRNA capabilities," said Alexander Zehnder, Chief Executive Officer at CureVac. "We have successfully executed on clinical programs in COVID-19 and flu as demonstrated by positive preliminary data reported in early 2023, validating our differentiated mRNA technology platform. We have acquired and successfully integrated Frame Cancer Therapeutics, adding state-of-the-art antigen discovery technologies to our expanding oncology footprint. The German pandemic preparedness agreement reached in April 2022 has accelerated the build-up of our commercial-scale GMP IV plant as a safeguard against future infectious disease outbreaks, forming an integral part of our highly scalable manufacturing landscape. With these key achievements, we have reached an inflection point. Future success will depend on strong execution discipline, which we will focus in 2023 on later stage clinical trials in prophylactic vaccines and initial clinical developments in oncology. As CureVac’s new CEO, I am deeply impressed by the vast potential of our technology as well as the scientific rigor and passion of our employees, and I am excited to build on our momentum to deliver on our goals in 2023."

"In 2022, CureVac experienced another year of significant transformation. We advanced our development from a biotech to a fully integrated biopharma company and achieved key milestones in both our clinical and corporate growth," said Pierre Kemula, Chief Financial Officer of CureVac. "Our 2022 income statement underlines this transformative period, phasing out the commitments related to our first-generation vaccine candidate and focusing on our second-generation programs co-financed by GSK, technical development and small to large scale manufacturing. The successful raise of $250 million in gross proceeds this February has significantly extended our financial runway for continued execution on our priorities in 2023 and beyond."

Selected Business Updates

Prophylactic Vaccines

Executing on Broad Second-Generation mRNA Vaccine Program, Jointly Developed with GSK

CureVac is executing on its broad clinical development program in prophylactic vaccines in collaboration with GSK and initiated four Phase 1 studies in COVID-19 and flu in 2022, testing both unmodified and modified mRNA candidates to identify the best performing candidate. Positive preliminary data reported in early 2023 confirmed modified mRNA as the preferred technology for further clinical development in the COVID-19 and seasonal flu vaccine program. All candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses. The second-generation mRNA backbone is expected to enable flexible protection against one or more emerging COVID-19 variants as well as other infectious diseases, such as flu and potential combinations against different viruses.

On January 6 and January 30, 2023, CureVac announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and flu. Preliminary results generated in younger as well as older adult populations showed that the constructs elicited promising immune responses starting at low doses as well as good reactogenicity profiles in both indications.

In the COVID-19 Phase 1 trial, the reported preliminary data for the tested monovalent vaccine candidate, CV0501, are based on cohort sizes of up to 20 participants in the younger adults age group (age 18-64) and 10 participants in the older adults age group (age ≥65). Previously reported safety data covered the 12, 25, 50, 100 and 200µg dose groups in the younger adult age group. Newly available data from 3 and 6µg dose levels in this age group show a consistent safety profile. One grade 3 solicited adverse event occurred in the 3µg dose group reported as fatigue. In the older adult age group, safety data were initially reported for doses levels of 12, 25 and 50µg. Newly available safety data for the 100 and 200µg dose levels showed no grade 3 solicited adverse events at these dose levels in this age group. CV0501 was shown to be generally well tolerated across both age groups and all dose levels. Immunogenicity data for the full dose ranges in both age groups showed relevant titers of neutralizing antibodies beginning at the lowest tested dose.

On day 29 at the 12µg dose level, CV0501 generated a ratio of post-boost to pre-boost serum neutralizing titers against the Omicron BA.1 variant of 8.1 in younger adults and 13.3 in older adults. The data read-outs for both age groups are currently being finalized.

While CV0501 encodes the Omicron BA.1 variant, a Phase 2 clinical study, expected to start later in 2023, will assess monovalent and bivalent vaccine candidates designed to target clinically relevant variants.

In the flu Phase 1 trial, preliminary data were reported on the tested monovalent construct Flu-SV-mRNA, expressing an H1N1 hemagglutinin antigen (subtype of influenza A). A number of doses ranging from 2 to 54µg with up to 25 subjects per dose cohort were evaluated in younger adults (age 18-45). In this age group, preliminary safety and reactogenicity data showed that Flu-SV-mRNA was generally well tolerated with no safety concerns observed to date across all tested dose levels. A single dose of Flu-SV-mRNA was assessed for safety and reactogenicity in older adults (age 60-80) and was also observed to be safe and well tolerated with no grade 3 adverse events in the 32 subjects who were administered the mRNA construct. Immunogenicity of the monovalent Flu-SV-mRNA was assessed in parallel with a licensed seasonal flu vaccine comparator in both age groups. In younger adults, adjusted geometric mean hemagglutinin inhibition antibody titers increased up to approximately 3.3 times those elicited by the licensed flu vaccine comparator. In older adults, adjusted geometric mean hemagglutinin inhibition antibody titers were approximately 2.3 times those elicited by the licensed flu vaccine comparator. In the same age group, the percentage of subjects achieving seroconversion was 89.7% for Flu-SV-mRNA and 56.2% for the licensed flu vaccine comparator.

The vaccine candidate for future clinical development in flu is expected to be a multivalent candidate, targeting all four strains recommended by the WHO. A combined Phase 1/2 study for multivalent vaccine candidates is expected to start in the second quarter of 2023.

Oncology

Broadening of Oncology Footprint with mRNA Cancer Vaccines –

Differentiated Antigen Discovery Approach

CureVac continues to execute on its strategy to develop the next generation of targeted mRNA-based cancer vaccines and expand in the oncology area with its differentiated antigen discovery approach. An initial portfolio of cancer vaccine candidates will be based on CureVac’s second-generation mRNA backbone, supported by its recent clinical validation in prophylactic vaccines. CureVac focuses on two approaches 1) the development of off-the-shelf cancer vaccines based on tumor antigens shared by different cancer patients and 2) the development of fully personalized cancer vaccines based on a patient’s individual tumor genomic profile. Innovation in cancer vaccine development is further enabled by CureVac’s proprietary lipid nanoparticle (LNP) research to further enhance T cell mediated immune responses for strongly immunogenic cancer vaccine candidates.

A previously announced clinical proof-of-principle study, which is designed to validate and optimize the second-generation mRNA backbone in an oncology setting, is on track to start in the second quarter of 2023. The Phase 1 study will test a single mRNA construct encoding for eight epitopes from tumor-associated antigens to assess the safety, immunogenicity and T cell-mediated immune activation in patients with surgically resected glioblastoma. Successful study setup and manufacture of clinical trial material of the complex mRNA construct represent important milestones that have already been achieved well in advance of the Phase 1 study starting, which is expected to enroll up to 54 patients at clinical sites in Germany, Belgium and the Netherlands.

A second previously announced clinical proof-of-principle study in patients with melanoma was anticipated to start in the second half of 2023. Following an extensive portfolio review, CureVac has refocused its clinical development in oncology. Instead of a proof-of-principle study, featuring an established full-length shared tumor antigen, CureVac expects to initiate a Phase 1 study assessing a state-of-the-art multiepitope design derived from CureVac’s proprietary antigen discovery platform. The study, which will be conducted in combination with PD-1 antibodies, is expected to start in 2024.

Lipid Nanoparticle mRNA Delivery

CureVac is advancing its research on proprietary lipid nanoparticles (LNP) for improved and targeted mRNA delivery within the body. At the European Molecular Biology Organization (EMBO) workshop in April this year, the company presented data on mRNA-LNP complexes of varied composition exhibiting distinct biological activities that open new routes for bespoke applications in prophylactic and cancer vaccines.

The presented in vitro and preclinical data demonstrate that targeted changes to the ratio or composition of the LNP constituents can be applied to fine tune LNP physicochemical properties and elicit distinct immune responses and biological activities. These data complement previously reported data on a new PEG-free LNP delivery system, which was preclinically shown to provide highly localized transcription of mRNA in the immune compartment and to be highly stable at room temperature as a dried presentation for an extended period.

Financial Update for the Fourth Quarter and Full-Year of 2022

Cash Position

Cash and cash equivalents amounted to €495.8 million on December 31, 2022, down from €811.5 million in the previous year. In 2022, cash was used for the funding of CureVac’s operations and R&D, the funding of the company’s new commercial-scale manufacturing facility, GMP IV, and the settling of contract manufacturing organization (CMO) contracts as part of the wind-down activities for CVnCoV, the company’s first-generation vaccine program. In 2021, cash used in operations was mainly allocated to prepayments to contract research organizations (CRO) and CMOs in relation to CVnCoV.

As of December 31, 2022, CureVac has settled most of its financial obligations related to CVnCoV. Looking forward, CureVac expects to see a decrease in cash outflows relating to the first-generation vaccine program. However, the company may have further cash outflows as it continues winding down CMO contracts associated with this program.

Revenues

Revenues amounted to €11.7 million and €67.4 million for the three and twelve months ended December 31, 2022, respectively, representing a decrease of €29.5 million and €35.6 million, from €41.2 million and €103.0 million, respectively, for the same periods in 2021.

The year-on-year decrease was primarily driven by the termination of the Boehringer Ingelheim collaboration in 2021, which led to revenue recognition of €26 million in that year.

Revenues from the two GSK collaborations decreased year-on-year by €12.0 million as the companies focused on the lead programs, flu and COVID-19. In the first quarter of 2022, CureVac received a €10 million milestone payment related to the initiation of the seasonal flu clinical trial. €6.3 million of this milestone was recognized pro rata as revenue in 2022. In 2022, total revenues of €62.3 million were recognized for both GSK collaboration agreements compared to €74.3 million in the prior year.

Operating Result

Operating loss amounted to €121.5 million and €249.5 million for the three and twelve months ended December 31, 2022, respectively, representing an increase of €116.0 million and a decrease of €162.8 million from an operating loss of €5.5 million and €412.3 million, respectively, for the same periods in 2021.

The operating result was affected by several key drivers:

· Cost of sales decreased primarily due to less expenses on CMO services. Prior year 2021 was impacted by significant expenses related to the set-up of a European CMO network for CVnCoV, CureVac’s first-generation vaccine program, including recognition of liabilities associated with winding down CMO contracts. This was partially offset in 2022 by an increase in write-off for raw materials, following the transfer to another party of reserved production capacity at a CMO.

· Research and development expenses decreased year-on-year primarily due to the termination of the CVnCoV Phase 2b/3 clinical study. 2021 R&D costs were mainly driven by the 40,000 subject Phase 2b/3 clinical trial for CVnCoV. Additionally, 2022 R&D costs were positively impacted by two elements amounting to €63.6 million:

o As of December 2021, CureVac had accrued all estimated remaining CVnCoV clinical trial costs. With the declining number of continuing study participants and re-negotiation of contracts in 2022, the remaining CVnCoV clinical trial costs estimate 6 decreased, resulting in the reversal of €38.5 million of the provision recorded in 2021.

This decrease was partially offset by increased materials consumed in research and development for the company’s programs.

o Additionally, 2022 R&D costs were positively impacted by a net gain from a change in the estimate in CMO contract termination provisions of €25.1 million, resulting primarily from the transfer to another party of committed capacity at a CMO in the first quarter of 2022.

· The fourth quarter of 2021 was impacted by income of €574.5 million from the release of governmental contract liabilities, related to the upfront payment from the European Commission (EC) and the grant from the German Federal Ministry of Education and Research (BMBF) after the withdrawal of CVnCoV from the regulatory approval process in October 2021; no such income was recognized in 2022.

· Other income decreased year-on-year but was positively impacted by €32.5 million in compensation for the reimbursement by another party of pre-payments and production activities set-up at a CMO. In 2021, other income was primarily attributable to amounts recognized from grants from the BMBF.

Financial Result (Finance Income and Expenses)

Net financial result for the three and twelve months ended December 31, 2022, was negative with €7.2 million and positive with €0.3 million, respectively, representing a decrease of €8.2 million and increase of €0.5 million from a profit of €1.0 million and a loss of €0.2 million for the same periods in 2021. Financial result was driven by foreign exchange impacts and interest on cash investments.

Pre-Tax Loss

Pre-tax loss was €128.7 million and €249.2 million for the three and twelve months ended December 31, 2022, compared to €4.5 million and €412.5 million in the same respective periods of 2021.

Conference call and webcast details

Dial-in numbers to participate in the conference call:

U.S. Toll-Free: +1-877-407-0989

International: +1-201-389-0921

Germany: 0800 182 0040

The live webcast link can be accessed via the newsroom section of the CureVac website at View Source

Corresponding presentation slides will be posted shortly before the start of the webcast.

A replay will be made available at this website after the event.

On April 25, 2023 Novartis reported its first quarter 2023 results (Presentation, Novartis, APR 25, 2023, View Source [SID1234630476]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!